Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet (London England). 2020;396:635–48. https://doi.org/10.1016/s0140-6736(20)31288-5.

Article  CAS  PubMed  Google Scholar 

Alsina M, Arrazubi V, Diez M, Tabernero J. Current developments in gastric cancer: from molecular profiling to treatment strategy. Nat Rev Gastroenterol Hepatol. 2023;20:155–70. https://doi.org/10.1038/s41575-022-00703-w.

Article  CAS  PubMed  Google Scholar 

Yuan DD, Zhu ZX, Zhang X, Liu J. Targeted therapy for gastric cancer: current status and future directions (review). Oncol Rep. 2016;35:1245–54. https://doi.org/10.3892/or.2015.4528.

Article  CAS  PubMed  Google Scholar 

Zhang D, Huang G, Liu J, Wei W. Claudin18.2-targeted cancer theranostics. Am J Nucl Med Mol Imaging. 2023;13:64–9.

PubMed  PubMed Central  Google Scholar 

Lei ZN, Teng QX, Tian Q, Chen W, Xie Y, Wu K, et al. Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduct Target Ther. 2022;7:358. https://doi.org/10.1038/s41392-022-01190-w.

Article  PubMed  PubMed Central  Google Scholar 

Sahin U, Türeci Ö, Manikhas G, Lordick F, Rusyn A, Vynnychenko I, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Annals Oncology: Official J Eur Soc Med Oncol. 2021;32:609–19. https://doi.org/10.1016/j.annonc.2021.02.005.

Article  CAS  Google Scholar 

Wang DW, Zhang WH, Danil G, Yang K, Hu JK. The role and mechanism of claudins in cancer. Front Oncol. 2022;12:1051497. https://doi.org/10.3389/fonc.2022.1051497.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cao W, Xing H, Li Y, Tian W, Song Y, Jiang Z, et al. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark Res. 2022;10:38. https://doi.org/10.1186/s40364-022-00385-1.

Article  PubMed  PubMed Central  Google Scholar 

Maron SB, Catenacci DV. Novel targeted therapies for Esophagogastric Cancer. Surg Oncol Clin N Am. 2017;26:293–312. https://doi.org/10.1016/j.soc.2016.10.002.

Article  PubMed  PubMed Central  Google Scholar 

Klempner SJ, Janjigian YY, Wainberg ZA. Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas. ESMO Open. 2023;8:100778. https://doi.org/10.1016/j.esmoop.2022.100778.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu G, Foletti D, Liu X, Ding S, Melton Witt J, Hasa-Moreno A, et al. Author correction: Targeting CLDN18.2 by CD3 bispecific and ADC modalities for the treatments of gastric and pancreatic Cancer. Sci Rep. 2019;9:16735. https://doi.org/10.1038/s41598-019-53130-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu G, Foletti D, Liu X, Ding S, Melton Witt J, Hasa-Moreno A, et al. Targeting CLDN18.2 by CD3 bispecific and ADC modalities for the treatments of gastric and pancreatic Cancer. Sci Rep. 2019;9:8420. https://doi.org/10.1038/s41598-019-44874-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Türeci Ӧ, Mitnacht-Kraus R, Wöll S, Yamada T, Sahin U. Characterization of zolbetuximab in pancreatic cancer models. Oncoimmunology. 2019;8:e1523096. https://doi.org/10.1080/2162402x.2018.1523096.

Article  CAS  PubMed  Google Scholar 

Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28:1189–98. https://doi.org/10.1038/s41591-022-01800-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arnold A, Daum S, von Winterfeld M, Berg E, Hummel M, Rau B, et al. Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas. Clin Transl Oncol. 2020;22:2357–63. https://doi.org/10.1007/s12094-020-02380-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arpa G, Fassan M, Guerini C, Quaquarini E, Grillo F, Angerilli V, et al. Claudin-18 expression in small bowel adenocarcinoma: a clinico-pathologic study. Virchows Arch. 2022;481:853–63. https://doi.org/10.1007/s00428-022-03393-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003;17:545–80. https://doi.org/10.1101/gad.1047403.

Article  CAS  PubMed  Google Scholar 

Chen Y, Hou X, Li D, Ding J, Liu J, Wang Z, et al. Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors. J Pharm Anal. 2023;13:367–75. https://doi.org/10.1016/j.jpha.2023.02.011.

Article  PubMed  PubMed Central  Google Scholar 

Hu G, Zhu W, Liu Y, Wang Y, Zhang Z, Zhu S, et al. Development and comparison of three (89)Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: a preclinical study. Eur J Nucl Med Mol Imaging. 2022;49:2634–44. https://doi.org/10.1007/s00259-022-05739-3.

Article  CAS  PubMed  Google Scholar 

Wang S, Qi C, Ding J, Li D, Zhang M, Ji C, et al. First-in-human CLDN18.2 functional diagnostic pet imaging of digestive system neoplasms enables whole-body target mapping and lesion detection. Eur J Nucl Med Mol Imaging. 2023. https://doi.org/10.1007/s00259-023-06234-z.

Article  PubMed  PubMed Central  Google Scholar 

Wei W, Zhang D, Zhang Y, Li L, Jin Y, An S, et al. Development and comparison of (68)Ga/(18)F/(64)Cu-labeled nanobody tracers probing Claudin18.2. Mol Ther Oncolytics. 2022;27:305–14. https://doi.org/10.1016/j.omto.2022.11.003.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao C, Rong Z, Ding J, Wang L, Wang B, Ding L, et al. Targeting Claudin 18.2 using a highly specific antibody enables Cancer diagnosis and guided surgery. Mol Pharm. 2022;19:3530–41. https://doi.org/10.1021/acs.molpharmaceut.1c00947.

Article  CAS  PubMed  Google Scholar 

Harmand TJ, Islam A, Pishesha N, Ploegh HL. Nanobodies as in vivo, non-invasive, imaging agents. RSC Chem Biol. 2021;2:685–701. https://doi.org/10.1039/d1cb00023c.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, et al. Phase I study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 expression in breast carcinoma. J Nucl Med. 2016;57:27–33. https://doi.org/10.2967/jnumed.115.162024.

Article  CAS  PubMed  Google Scholar 

Qi C, Guo R, Chen Y, Li C, Liu C, Zhang M, et al. (68)Ga-NC-BCH whole-body PET imaging rapidly targets Claudin18.2 in lesions in gastrointestinal Cancer patients. J Nucl Med. 2024. https://doi.org/10.2967/jnumed.123.267110.

Article  PubMed  PubMed Central  Google Scholar 

Li L, Liu T, Shi L, Zhang X, Guo X, Hu B, et al. HER2-targeted dual radiotracer approach with clinical potential for noninvasive imaging of trastuzumab-resistance caused by epitope masking. Theranostics. 2022;12:5551–63. https://doi.org/10.7150/thno.74154.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma X, Zhou X, Hu B, Li X, Yao M, Li L, et al. Preclinical evaluation and pilot clinical study of [(68)Ga]Ga-THP-APN09, a novel PD-L1 targeted nanobody radiotracer for rapid one-step radiolabeling and PET imaging. Eur J Nucl Med Mol Imaging. 2023;50:3838–50. https://doi.org/10.1007/s00259-023-06373-3.